Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2013

Open Access 01-12-2013 | Original basic research

VacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 on human platelets

Authors: Kaneo Satoh, Toshiya Hirayama, Katsuhiro Takano, Katsue Suzuki-Inoue, Tadashi Sato, Masato Ohta, Junko Nakagomi, Yukio Ozaki

Published in: Thrombosis Journal | Issue 1/2013

Login to get access

Abstract

Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induced platelet CD62P expression. However, VacA reacted with none of the alleged VacA receptors present on platelet membranes. We therefore analyzed VacA associated proteins obtained through VacA affinity chromatography, using MALDI-TOF-MS. Multimerin1 was detected in two consecutive experiments, as the binding protein for VacA. Plasmon resonance confirmed their binding, and dot blot analysis revealed that the peptide sequence AA 321-340 of multimerin 1 is the binding site for VacA. In conclusion, we propose a new interaction between multimerin1 and VacA , which may give another insight into H. pylori-induced platelet activations under H. pylori infection.
Appendix
Available only for authorised users
Literature
1.
Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J Med 2002, 346: 995-1008. 10.1056/NEJMra010501CrossRefPubMed
2.
Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB: Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009, 113: 1231-1240. 10.1182/blood-2008-07-167155CrossRefPubMed
3.
Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G: Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998, 352: 878.CrossRefPubMed
4.
Elizalde JI, Gómez J, Panés J, Lozano M, Casadevall M, Ramírez J, Pizcueta P, Marco F, Rojas FD, Granger DN, Piqué JM: Platelet activation in mice and human Helicobacter pylori infection. J Clin Invest 1997, 100: 996-1005. 10.1172/JCI119650PubMedCentralCrossRefPubMed
5.
Ahn ER, Tiede MP, Jy W, Bidot CJ, Fontana V, Ahn YS: Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. Acta Hamatologica 2006, 116: 19-24. 10.1159/000092343CrossRef
6.
Byrne MF, Kerrigan SW, Corcoran PA, Atherton JC, Murray FE, Fitzgerald DJ, Cox DM: Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003, 124: 1846-1854. 10.1016/S0016-5085(03)00397-4CrossRefPubMed
7.
Kalia N, Jacob S, Brown NJ, Reed MW, Morton D, Bardhan KD: Studies on the gastric mucosal microcirculation. Helicobacter pylori water soluble extracts induce platelet aggregation in the gastric mucosal microcirculation in vivo. Gut 1997, 41: 748-752. 10.1136/gut.41.6.748PubMedCentralCrossRefPubMed
8.
Odenbreit S, Püls J, Sedlmaier B, Gerland E, Fischer W, Haas R: Translocation of Helicobactor pylori CagA into gastric epithelical cells by type VI secretion. Science 2000, 287: 1497-1500. 10.1126/science.287.5457.1497CrossRefPubMed
9.
Cover TL, Blaser MJ: Purification and characterization of the vacuolating toxin from Helicobactor pylori. J Biol Chem 1992, 267: 10570-10575.PubMed
10.
Fischer W, Buhrdorf R, Gerland E, Haas R: Outer membrane targeting of passenger proteins by the vacuolating cytotoxin autotransporter of Helicobactor pylori. Infect Immun 2001, 69: 6769-6775. 10.1128/IAI.69.11.6769-6775.2001PubMedCentralCrossRefPubMed
11.
Cover TL: An intracellular target for Helicobacter pylori vacuolating toxin. Trends Microbiol 1998, 6: 127-128. 10.1016/S0966-842X(98)01231-1CrossRefPubMed
12.
Manetti R, Massari P, Burroni D, De Bernard M, Marchini A, Olivieri R, Papini E, Montecucco C, Rappuoli R, Telford JL: Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies. Infect Immun 1995, 63: 4476-4480.PubMedCentralPubMed
13.
Nakayama M, Kimura M, Wada A, Yahiro K, Ogushi K, Niidome T, Fujikawa A, Shirasaka D, Aoyama N, Kurazono H, Noda M, Moss J, Hirayama T: Helicobacter pylori VacA activates the p38/activating transcription factor 2-mediated signal pathway in AZ-521 cells. J Biol Chem 2004, 279: 7024-7028.CrossRefPubMed
14.
Suzuki-Inoue K, Inoue O, Frampton J, Watson SP: Murine GPVI stimulates weak integrin activation in PLC{gamma}2–/– platelets: involvement of PLC{gamma}1 and PI 3-kinase. Blood 2003, 102: 1367-1373. 10.1182/blood-2003-01-0029CrossRefPubMed
15.
Yahiro K, Niidome T, Kimura M, Hatakeyama T, Aoyagi H, Kurazono H, Imagawa K, Wada A, Moss J, Hirayama T: Activation of Helicobacter pylori VacA toxin by alkaline or acid conditions increases its binding to a 250-kDa receptor protein-tyrosine phosphatase beta. J Biol Chem 1999, 274: 36693-36699. 10.1074/jbc.274.51.36693CrossRefPubMed
16.
Seto K, Hayashi-Kuwabara Y, Yoneta T, Suda H, Tamaki H: Vacuolation induced by cytotoxin from Helicobacter pylori is mediated by the EGF receptor in HeLa cells. FEBS Lett 1998, 431: 347-350. 10.1016/S0014-5793(98)00788-1CrossRefPubMed
17.
Yahiro K, Wada A, Nakayama M, Kimura T, Ogushi K, Niidome T, Aoyagi H, Yoshino K, Yonezawa K, Moss J, Hirayama T: Protein-tyrosine phosphatase alpha, RPTP alpha, is a Helicobacter pylori VacA receptor. J Biol Chem 2003, 278: 19183-19189. 10.1074/jbc.M300117200CrossRefPubMed
18.
Fujikawa A, Shirasaka D, Yamamoto S, Ota H, Yahiro K, Fukada M, Shintani T, Wada A, Aoyama N, Hirayama T, Fukamachi H, Noda M: Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet 2003, 33: 375-381. 10.1038/ng1112CrossRefPubMed
19.
Sewald X, Gebert-Vogl B, Prassl S, Barwig I, Weiss E, Fabbri M, Osicka R, Schiemann M, Busch DH, Semmrich M, Holzmann B, Sebo P, Haas R: Integrin subunit CD18 is the T-lymphocyte receptor for the Helicobacter pylori vacuolating cytotoxin. Cell Host Microbe 2008, 3: 20-29. 10.1016/j.chom.2007.11.003CrossRefPubMed
20.
Guo J, Piguet PF: Stimulation of thrombocytopoiesis decreases platelet beta2 but not beta1 or beta3 integrins. Br J Haematol 1998, 100: 712-719. 10.1046/j.1365-2141.1998.00618.xCrossRefPubMed
21.
Canziani GA, Klakamp S, Myszka DG: Kinetic screening of antibodies from crude hybridoma samples using Biacore. Anal Biochem 2004, 325: 301-307. 10.1016/j.ab.2003.11.004CrossRefPubMed
22.
Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D: Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60: 237-246. 10.1093/jac/dkm195CrossRefPubMed
23.
Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, Okubo M, Zaitsu Y, Ariyoshi K, Nakamura Y, Nawata R, Oka Y, Shirai M, Tanizawa Y: Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004, 124: 91-96. 10.1046/j.1365-2141.2003.04735.xCrossRefPubMed
24.
Bai Y, Wang Z, Bai X, Yu Z, Cao L, Zhang W, Ruan C: Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int J Hematol 2009, 89: 142-149. 10.1007/s12185-008-0247-4CrossRefPubMed
25.
Jeimy SB, Tasneem S, Cramer EM, Hayward CP: Multimerin 1. Platelets 2008, 19: 83-95. 10.1080/09537100701832157CrossRefPubMed
26.
Hayward CP, Smith JW, Horsewood P, Warkentin TE, Kelton JG: p-155, a multimeric platelet protein that is expressed on activated platelets. J Biol Chem 1991, 266: 7114-7120.PubMed
27.
Adam F, Zheng S, Joshi N, Kelton DS, Sandhu A, Suehiro Y, Jeimy SB, Santos AV, Massé JM, Kelton JG, Cramer EM, Hayward CP: Analysis of cellular multimerin 1 receptors: in vitro evidence of binding mediated by αIIbβ3 and αvβ3. Thromb Haemost 2005, 94: 1004-1011.PubMed
28.
Jeimy SB, Fuller N, Tasneem S, Segers K, Stafford AR, Weitz JI, Camire RM, Nicolaes GA, Hayward CP: Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. Thromb Haemost 2008, 100: 1058-1067.PubMed
Metadata
Title
VacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 on human platelets
Authors
Kaneo Satoh
Toshiya Hirayama
Katsuhiro Takano
Katsue Suzuki-Inoue
Tadashi Sato
Masato Ohta
Junko Nakagomi
Yukio Ozaki
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2013
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-11-23

Other articles of this Issue 1/2013

Thrombosis Journal 1/2013 Go to the issue

Case report

Protein-C deficiency presenting as pulmonary embolism and myocardial infarction in the same patient

Original clinical investigation

Prothrombotic markers in patients with acute myocardial infarction and left ventricular thrombus formation treated with pci and dual antiplatelet therapy

Review

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia

Case report

Postpartum deep vein thrombosis and pulmonary embolism in twin pregnancy: undertaking of clinical symptoms leading to massive complications

Review

The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature

Original basic research

Purification and characterization of mutant miniPlasmin for thrombolytic therapy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits